Pacific Biosciences initiated with a Neutral at UBS

UBS analyst John Sourbeer initiated coverage of Pacific Biosciences with a Neutral rating and $13 price target. The firm’s proprietary analysis and expert calls drive its projected 42% revenue CAGR ~in-line with consensus, and says that Pacific is launching into an increasingly competitive NGS market with lingering macro pressures, the analyst tells investors in a research note.